A Phase I Study of Xevinapant With Radiation and Concurrent Carboplatin and Paclitaxel in Patients Ineligible for Cisplatin With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck

University of Chicago1 个研究点分布在 1 个国家目标入组 42 人开始时间: 2024年1月24日最近更新: 2025年6月8日

适应症

干预措施

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: University of Chicago
入组人数: 42
试验地点: 1
主要终点: Determine best safe dose of xevinapant when given in combination with radiation and chemotherapy

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The goal of this clinical trial is to determine the best safe dose of xevinapant that can be given in combination with chemotherapy and radiation in patients with head and neck cancer. Up to 4 doses of xevinapant will be tested in the dose escalation portion of the study. After the best safe dose is found during escalation, an additional group of participants will be enrolled at that dose to learn more about the treatment combination (dose expansion).

The main question[s] it aims to answer are:

what is the maximum safe dose that can be given
what dose should be used in subsequent (phase 2) trials

Participants will receive xevinapant in combination with paclitaxel and carboplatin chemotherapy and radiation. Treatment will be given in 3-week cycles for 3 cycles.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Sequential
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Pathologically proven diagnosis of squamous cell carcinoma of the head and neck (HNSCC) of the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, or sinuses.
•Patients with oropharynx cancer need p16 determination by immunohistochemistry (where positive is defined as greater than 70% strong nuclear or nuclear and cytoplasmic staining of tumor cells).
•Oral cavity, larynx, hypopharynx, or p16-negative oropharynx cancer must be stages T1-2N1-3 or T3-4N0-3 (AJCC 8th edition). Sinus primary must be T4bN0-3 not amenable to surgical resection.
•P16-positive oropharynx cancer patients, stages T1-2N1-3 or T3-4N0-3 (AJCC 8th edition staging).
•The patient has unresected, measurable disease as defined by the presence of at least one measurable lesion per RECIST 1.
•Age >= 18 years of age
•Patients must have a contraindication to cisplatin
•Performance Status of 0-2
•Adequate hematologic function
•White Blood Cell Count (WBC) >= 2000 cells/mm3
•Absolute neutrophil count (ANC) >= 1,500 cells/mm3
•Platelets >= 100,000 cells/mm3
•Hemoglobin >= 9.0 g/dL
•Adequate renal function was defined as follows: Creatinine clearance (CrCl) > 30 mL/min
•Adequate hepatic function
•Total bilirubin <= 1.5 x upper limit of normal (ULN) (except patients with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dL)
•aspartate aminotransferase (AST) and alanine transaminase (ALT) <= 2.5 x upper limit of normal (ULN)
•For women of childbearing potential (e.g. uterus present and menstruating), a negative serum pregnancy test within 14 days prior to registration.
•Willingness to agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from time of joining the study until 6 months after completing chemotherapy treatment or 3 months after last dose of xevinapant, whichever is the latest.
•Patients with a history of hepatitis B or C infection are eligible if they have an undetectable viral load.
•Ability to understand and the willingness to sign a written informed consent document.
•Availability of tumor tissue for research analysis. Patients who do not have adequate tissue available will need to undergo a new biopsy prior to enrollment on study.

排除标准

•Definitive clinical or radiologic evidence of distant (beyond cervical lymph node and neck tissue) metastatic disease.
•Carcinoma of the neck of unknown primary site of origin
•Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable if not within < 3 years
•Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields;
•Severe, active co-morbidity defined as follows:
•History of bone marrow transplant and organ transplant, including allogeneic stem cell transplantation.
•Unstable angina requiring hospitalization in the last 6 months.
•New York Heart Association Functional Classification III/IV.
•Myocardial infarction within the last 6 months.
•Persistent Grade 3-4 electrolyte abnormalities that cannot be reversed despite as indicated by repeat testing.
•Ongoing active infection associated with symptoms and/or requires antibiotic therapy at the time of initiation of treatment.
•Pregnancy and nursing females, if applicable.
•Receipt of live vaccinations within 28 days prior to study start.
•Patients who are receiving any other investigational agents.
•Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years.
•History of allergic reactions attributed to compounds of similar chemical or biologic composition to xevinapant, carboplatin, or paclitaxel.
•Patients taking prohibited medications and those requiring close monitoring.

研究组 & 干预措施

Escalation Group Dose Level 1

Experimental

Participants assigned to this cohort will receive xevinapant 150 mg for 2 out of every 3 weeks (Daily on days 1-14 of a 21-day cycle). They will also receive carboplatin and paclitaxel weekly for 7 doses with radiation (chemoRT).